Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2000

View Archived Issues

Enrollment completed in European phase III trial of platelet pathogen inactivation system

FDA approves modifications to Dermagraft IDE for diabetic foot ulcers

Agouron solves atomic structure of Chk1, a cell cycle-regulating protein

SBIR grant to Antigen Express for MHC class II-enhanced cancer vaccines

Gliatech's anticomplement MAb reduces inflammation in preclinical model

AxyS Pharmaceuticals ends 1999 with three key programs in preclinical testing

Baxter and AlphaOne to codevelop rAAT treatment of hereditary emphysema

Phase II trial of Oncophage begins for treatment of NHL

Columbia Laboratories reacquires U.S. rights to Advantage-S

Millennium and MorphoSys expand antibody development agreement

SkyePharma and Bioglan establish marketing agreement for Solarase

Esteve and DevCo collaborate on neuroscience program

Ilex Oncology initiates second phase I trial of ILX-23-7553

Ligand moves LGD-2226 towards human studies

IND filed with FDA for ISAtx-247

New cephalosporin antibiotics for beta-lactam-resistant infections

Microbially produced antitumor antibiotics discovered at Mercian

Abeta peptide formation inhibitors from Roche for the treatment of AD

Takeda's new benzothiepin derivatives enhance bone formation

International patent issued for SB's novel C3A receptor ligands and their use in inflammation

Antiplatelet agents designed at Toray with affinity for thromboxane and prostanoid receptors

Merck compound L-754030 and use in circadian rhythm disorders covered by new patent

Pivotal trial data presented at ACC meeting support use of Novastan in HIT

Genentech outlines clinical trial plan for TNKase in combination with leading antithrombotics

Ebelsen studied in models of lung injury, lung inflammation

E-5564 proves safe and effective in humans with experimentally induced endotoxemia

Pharmacokinetics, efficacy and safety of PNU-83757 examined in patients with ED

Leukocytosis following AMD-3100 is dose-related and reversible

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.